Luminex Corporation Receives FDA Clearance for New, Front Line Respiratory Viral Panel Test

Luminex Corporation LMNX announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its xTAG Respiratory Viral Panel FAST. This front line test has the potential to significantly change the way respiratory viral testing is performed and complements the company's existing respiratory portfolio.